Also, on February 23, 2019, the Company presented a poster with data from the ZENITH-1 trial of BCX7353 for the acute treatment of hereditary angioedema attacks at the American Academy of Allergy, Asthma & Immunology, or AAAAI, annual meeting, and published the poster on the investor relations section of the Company’s website. The poster presented at AAAAI and published on the Company’s website contained a typographical error, which incorrectly noted in the table titled RESULTS—SAFETY that a serious treatment-emergent adverse event, or TEAE occurred after treatment of 1 attack with 750 mg and 0 attacks treated with placebo. The table should have noted that a serious TEAE occurred after treatment of 0 attacks with 750 mg and 1 attack treated with placebo.  On February 25, 2019, the Company published the corrected poster to the Company’s website.  

On February 23, 2019, the Company issued a news release describing the events in this Item 7.01.  A copy of the news release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.   On February 25, 2019, the Company published the corrected poster describing the events in this Item 7.01.  A copy of the corrected poster is furnished as Exhibit 99.2 hereto and is incorporated herein by reference.

The information furnished in this Item 7.01, including Exhibits 99.1 and Exhibits 99.2,  shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject  to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing made by the Company under the Exchange Act or the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such filing.

Forward Looking Statements

This Current Report on Form 8-K contains forward-looking statements, including statements regarding future results, performance or achievements. These statements involve known and unknown risks, uncertainties and other factors which may cause BioCryst’s actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and are subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Some of the factors that could affect the forward-looking statements contained herein include: that ongoing and future preclinical and clinical development of HAE second generation drug candidates (including APeX-2, APeX-S and APeX-J) may not have positive results, may be more expensive or may not move as quickly as planned; that the FDA, EMA or other applicable regulatory agency may not provide regulatory clearances which may result in delay of planned clinical trials or failure to achieve market approval for product candidates. Please refer to the documents BioCryst files periodically with the Securities and Exchange Commission, specifically BioCryst’s most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K, all of which identify important factors that could cause the actual results to differ materially from those contained in BioCryst’s projections and forward-looking statements.